Differences in Comorbidities Explain Black-White Disparities in Outcomes After Femoropopliteal Endovascular Intervention
- PMID: 35695005
- PMCID: PMC9308741
- DOI: 10.1161/CIRCULATIONAHA.122.058998
Differences in Comorbidities Explain Black-White Disparities in Outcomes After Femoropopliteal Endovascular Intervention
Abstract
Background: Black adults have a higher incidence of peripheral artery disease and limb amputations than White adults in the United States. Given that peripheral endovascular intervention (PVI) is now the primary revascularization strategy for peripheral artery disease, it is important to understand whether racial differences exist in PVI incidence and outcomes.
Methods: Data from fee-for-service Medicare beneficiaries ≥66 years of age from 2016 to 2018 were evaluated to determine age- and sex-standardized population-level incidences of femoropopliteal PVI among Black and White adults over the 3-year study period. Patients' first inpatient or outpatient PVIs were identified through claims codes. Age- and sex-standardized risks of the composite outcome of death and major amputation within 1 year of PVI were examined by race.
Results: Black adults underwent 928 PVIs per 100 000 Black beneficiaries compared with 530 PVIs per 100 000 White beneficiaries (risk ratio, 1.75 [95% CI, 1.73-1.77]; P<0.01). Black adults who underwent PVI were younger (mean age, 74.5 years versus 76.4 years; P<0.01), were more likely to be female (52.8% versus 42.7%; P<0.01), and had a higher burden of diabetes (70.6% versus 56.0%; P<0.01), chronic kidney disease (67.5% versus 56.6%; P<0.01), and heart failure (47.4% versus 41.7%; P<0.01) than White adults. When analyzed by indication for revascularization, Black adults were more likely to undergo PVI for chronic limb-threatening ischemia than White adults (13 023 per 21 352 [61.0%] versus 59 956 per 120 049 [49.9%]; P<0.01). There was a strong association between Black race and the composite outcome at 1 year (odds ratio, 1.21 [95% CI, 1.16-1.25]). This association persisted after adjustment for socioeconomic status (odds ratio, 1.08 [95% CI, 1.03-1.13]) but was eliminated after adjustment for comorbidities (odds ratio, 0.96 [95% CI, 0.92-1.01]).
Conclusions: Among fee-for-service Medicare beneficiaries, Black adults had substantially higher population-level PVI incidence and were significantly more likely to experience adverse events after PVI than White adults. The association between Black race and adverse outcomes appears to be driven by a higher burden of comorbidities. This analysis emphasizes the critical need for early identification and aggressive management of peripheral artery disease risk factors and comorbidities to reduce Black-White disparities in the development and progression of peripheral artery disease and the risk of adverse events after PVI.
Keywords: healthcare disparities; peripheral arterial disease.
Conflict of interest statement
Conflicts of Interest/Disclosures
Dr. Krawisz receives grant support from the John S. LaDue Memorial Fellowship. Dr. Yeh reports grant support from AstraZeneca, Abbott Vascular, BD Bard, Boston Scientific, Cook Medical, Medtronic, Microport, and Philips; consulting fees from Abbott Vascular, AstraZeneca, Boston Scientific, Medtronic, Shockwave, and Zoll. Dr. Jaff is a part-time employee of Boston Scientific; he is an advisor to Gilde; he is an equity investor in Efemoral, Embolitech, R3 Vascular, Vactronix, Venarum. Dr. Giri reports research funds from Boston Scientific, Inari Medical, Abiomed, and BioSense Webster; he is on the advisory Boards for Boston Scientific, Inari Medical, and Astra Zeneca. Dr. Julien reports stock in Johnson & Johnson and Shockwave medical. Dr. Secemsky reports grant support from NIH/NHLBI K23HL150290, the Food & Drug Administration, Harvard Medical School’s Shore Faculty Development Award, AstraZeneca, BD, Boston Scientific, Cook, CSI, Laminate Medical, Medtronic and Philips; he reports consulting fees from Abbott, Bayer, BD, Boston Scientific, Cook, CSI, Endovascular Engineering, Inari, Janssen, Medtronic, Philips, and VentureMed. All other authors have nothing to disclose.
Figures


Similar articles
-
Racial and ethnic disparities in major adverse limb events persist for chronic limb threatening ischemia despite presenting limb threat severity after peripheral vascular intervention.J Vasc Surg. 2023 Mar;77(3):848-857.e2. doi: 10.1016/j.jvs.2022.10.043. Epub 2022 Nov 2. J Vasc Surg. 2023. PMID: 36334848
-
Editor's Choice - Infrapopliteal Peripheral Vascular Interventions for Claudication are Performed Frequently in the USA and Are Associated with Poor Long Term Outcomes.Eur J Vasc Endovasc Surg. 2025 Jan;69(1):89-101. doi: 10.1016/j.ejvs.2024.06.017. Epub 2024 Jun 19. Eur J Vasc Endovasc Surg. 2025. PMID: 38906366
-
Racial disparities in the use of revascularization before leg amputation in Medicare patients.J Vasc Surg. 2011 Aug;54(2):420-6, 426.e1. doi: 10.1016/j.jvs.2011.02.035. Epub 2011 May 14. J Vasc Surg. 2011. PMID: 21571495 Free PMC article.
-
Exploring Prognostic Implications of Race and Ethnicity in Patients With Peripheral Arterial Disease.J Surg Res. 2024 Oct;302:739-754. doi: 10.1016/j.jss.2024.07.120. Epub 2024 Aug 30. J Surg Res. 2024. PMID: 39216457
-
Disparities in Diagnosis, Treatment, and Outcomes of Peripheral Artery Disease: JACC Scientific Statement.J Am Coll Cardiol. 2023 Dec 12;82(24):2312-2328. doi: 10.1016/j.jacc.2023.09.830. J Am Coll Cardiol. 2023. PMID: 38057074 Review.
Cited by
-
Practice patterns of peripheral vascular interventions for peripheral artery disease in the office-based laboratory setting versus outpatient hospital.J Vasc Surg. 2024 Nov;80(5):1525-1536.e7. doi: 10.1016/j.jvs.2024.06.006. Epub 2024 Jun 20. J Vasc Surg. 2024. PMID: 38908807
-
Trends and Factors Associated With Peripheral Vascular Interventions for the Treatment of Claudication From 2011 to 2022: A National Medicare Cohort Study.J Am Heart Assoc. 2024 Jul 16;13(14):e033463. doi: 10.1161/JAHA.123.033463. Epub 2024 Jul 3. J Am Heart Assoc. 2024. PMID: 38958132 Free PMC article.
-
Racial and Ethnic Disparities in Treatment of Critical Limb Ischemia: A National Perspective.J Am Heart Assoc. 2023 Sep 5;12(17):e029074. doi: 10.1161/JAHA.122.029074. Epub 2023 Aug 23. J Am Heart Assoc. 2023. PMID: 37609984 Free PMC article.
-
Racial and Socioeconomic Health Disparities in Peripheral Artery Disease.J Am Heart Assoc. 2024 Nov 5;13(21):e031446. doi: 10.1161/JAHA.123.031446. Epub 2024 Nov 4. J Am Heart Assoc. 2024. PMID: 39494562 Free PMC article. Review.
-
Racial Variability in Platelet Response Among Patients With Peripheral Artery Disease.J Surg Res. 2025 Mar;307:107-115. doi: 10.1016/j.jss.2025.01.022. Epub 2025 Feb 25. J Surg Res. 2025. PMID: 40009898
References
-
- Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, Boehme AK, Buxton AE, Carson AP, Commodore-Mensah Y, et al. Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association. Circulation 2022;145:e153–e639. doi:10.1161/CIR.0000000000001052 - DOI - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical